阿司匹林抗结直肠癌的作用机制的生物信息学分析

doi:10.3969/j.issn.1000-8535.2021.06.006

摘要/Abstract

摘要： 目的通过生物信息学方法,分析阿司匹林抗结直肠癌的作用机制。方法在DrugBank 5.1.5中查找阿司匹林的直接作用蛋白靶点(direct protein targets,DPTs);构建阿司匹林DPTs的蛋白质-蛋白质相互作用(protein-protein interaction,PPI)网络并分析相关信号通路;从GEO数据库中获取结直肠癌表达谱芯片数据,筛选中心度最高的20个结直肠癌差异表达基因作为Hub基因;将DPTs相互关联基因与结直肠癌Hub基因求交集,确认阿司匹林抗结直肠癌的潜在作用靶点,分析其在TCGA数据库结肠腺癌样本中的表达情况,并进行GO功能富集分析和KEGG信号通路分析。最终通过RT-PCR和WB实验验证阿司匹林抗结直肠癌的潜在靶点。结果在DrugBank 5.1.5中确定了11个阿司匹林DPTs,KEGG信号通路分析发现其中6个DPTs(EDNRA,IKBKB,NFKB2,NFKBIA,PTGS2,TP53)与癌症的发生发展有关。将DPTs相关联基因与筛选的20个结直肠癌Hub基因求交集,发现5个基因(CDK1,AURKA,CCNB1,MAD2L1,TPX2)可能是阿司匹林抗结直肠癌的潜在作用靶点,其在TCGA数据库结肠腺癌样本中均表达上调,基因功能主要富集于细胞周期调控。RT-PCR和WB实验结果显示阿司匹林可以降低人结肠癌细胞中CDK1,AURKA,CCNB1,MAD2L1,TPX2的mRNA水平和蛋白表达。结论 CDK1,AURKA,CCNB1,MAD2L1,TPX2可能是阿司匹林抗结直肠癌的潜在靶点,其可能通过影响细胞周期调控发挥抗肿瘤作用。

关键词: 阿司匹林, 结直肠癌, 生物信息学, 细胞周期

Abstract: Objective To analyze the mechanism of aspirin against colorectal cancer(CRC)by bioinformatic analysis. Methods DrugBank 5.1.5 was used to identify direct protein targets (DPTs) of aspirin. The protein-protein interaction (PPI) network of DPTs was constructed and involved signaling pathways were analyzed. CRC-associated gene expression datasets were downloaded from GEO database, and the top twenty differentially expressed genes with the highest degree were screened out as Hub genes. Common genes between the genes associated with the DPTs and the Hub genes of CRC were the potential targets of aspirin against CRC. The potential targets in TCGA database colon adenocarcinoma (COAD) samples were examined. GO functional enrichment analysis and KEGG signaling pathway analysis of the potential targets were performed. The potential targets of aspirin against CRC cells were verified by reverse transcription-polymerase chain reaction (RT-PCR) and western blot (WB). Results Eleven DPTs of aspirin were identified in DrugBank 5.1.5. KEGG signaling pathway showed that 6 genes (EDNRA, IKBKB, NFKB2, NFKBIA, PTGS2, TP53) were associated with the occurrence and development of CRC. By intersecting 20 Hub genes of CRC with genes associated with the DPTs of aspirin, it was found that 5 genes (CDK1, AURKA, CCNB1, MAD2L1, TPX2) might be the potential targets of aspirin against CRC. They were all up-regulated in TCGA-COAD samples, and the gene functions were mainly enriched in cell cycle regulation. The results of RT-PCR and WB showed that aspirin could down-regulate the mRNA and protein expression levels of CDK1, AURKA, CCNB1, MAD2L1 and TPX2 in human colon cancer cells respectively. Conclusion CDK1, AURKA, CCNB1, MAD2L1 and TPX2 could be potential targets of aspirin against CRC by affecting the progress of cell cycle regulation.

Key words: aspirin, colorectal cancer, bioinformatics, cell cycle

郎吉萍, 戴秋月, 吕萍, 郭志刚. 阿司匹林抗结直肠癌的作用机制的生物信息学分析[J]. 广州医药, 2021, 52(6): 23-34.

LANG Jiping, DAI Qiuyue, LV Ping, GUO Zhigang. Bioinformatic analysis of mechanism of aspirin against colorectal cancer[J]. Guangzhou Medical Journal, 2021, 52(6): 23-34.

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] KEUM N, GIOVANNUCCI E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(12):713-732.
[3] FENG R M, ZONG Y N, CAO S M, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun, 2019, 39(1):22.
[4] DREW D A, CAO Y, CHAN A T. Aspirin and colorectal cancer: the promise of precision chemoprevention[J]. Nat Rev Cancer, 2016, 16(3):173-186.
[5] KATONA B W, WEISS J M. Chemoprevention of colorectal cancer[J]. Gastroenterology, 2020, 158(2):368-388.
[6] BARON J A, COLE B F, SANDLER R S, et al. A randomized trial of aspirin to prevent colorectal adenomas[J]. N Engl J Med, 2003, 348(10):891-899.
[7] BENAMOUZIG R, UZZAN B, DEYRA J, et al. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial[J]. Gut, 2012, 61(2):255-261.
[8] SANDLER R S, HALABI S, BARON J A, et al. A Randomized trial of aspirin to prevent colorectal adenomas in patients with previous[J]. N Engl J Med, 2003,348(10):883-890.
[9] CHUBAK J, WHITLOCK E P, WILLIAMS S B, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force[J]. Ann Int Med, 2016, 164(12):814.
[10] TADANOBU S, SHUSUKE T, KOMAROVA N L, et al. A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer[J]. Carcinogenesis, 2020, 41(6):751-760.
[11] BIBBINS-DOMINGO K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force commendation statement[J]. Ann Int Med, 2016, 164(12): 836-845.
[12] PATRIGNANI P, SACCO A, SOSTRES C, et al. Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer[J]. Clin Pharmacol Ther, 2017, 102(1):52-61.
[13] RANGER S, GURPREET. Therole of aspirin in colorectal cancer chemoprevention[J]. Crit Rev Oncol Hemat, 2016(104):87-90.
[14] GOEL A, CHANG D K, RICCIARDIELLO L, et al. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells[J]. Clin Cancer Res, 2003, 9(1):383-390.
[15] GONG L, ZHANG D, DONG Y, et al. Integratedbioinformatics analysis for identificating the therapeutic targets of aspirin in small cell lung cancer[J]. J Biomed Inform, 2018(88):20-28.
[16] LIU Y, LIANG Y, WISHART D. PolySearch2: a significantly improved text-mining system for discovering associations between human diseases, genes, drugs, metabolites, toxins and more[J]. Nucleic Acids Res, 2015, 43(W1):W535-W542.
[17] SZKLARCZYK D, MORRIS J H, COOK H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible[J]. Nucleic Acids Res, 2017, 45(D1):D362-D368.
[18] SHANNON P, MARKIEL A, OZIER O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11):2498-2504.
[19] CERAMI E, GAO J, DOGRUSOZ U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5):401-404.
[20] GAO J, AKSOY B A, DOGRUSOZ U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269):pl1.
[21] HONG Y, DOWNEY T, EU K W, et al. A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics[J]. Clin Exp Metastasis, 2010, 27(2):83-90.
[22] TSUKAMOTO S, ISHIKAWA T, IIDA S, et al. Clinical significance ofosteoprotegerin expression in human colorectal cancer[J]. Clin Cancer Res, 2011, 17(8):2444-2450.
[23] KHAMAS A, ISHIKAWA T, SHIMOKAWA K, et al. Screening for epigenetically masked genes in colorectal cancer using 5-Aza-2′-deoxycytidine, microarray and gene expression profile[J]. Cancer Genomics Proteomics, 2012, 9(2):67-75.
[24] IWAYA T, YOKOBORI T, NISHIDA N, et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway[J]. Carcinogenesis, 2012, 33(12):2391-2397.
[25] TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1):W98-W102.
[26] GIANNAKIS M, MU X J, SHUKLA S A, et al. Genomiccorrelates of immune-cell infiltrates in colorectal carcinoma[J]. Cell Rep, 2016, 15(4):857-865.
[27] SESHAGIRI S, STAWISKI E W, DURINCK S, et al. Recurrent R-spondin fusions in colon cancer[J]. Nature, 2012, 488(7413):660-664.
[28] SUNG W W, LIN Y M, WU P R, et al. High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients[J]. BMC Cancer, 2014, 14(1):951.
[29] YANG J, XU W W, HONG P, et al. Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction[J]. Cancer Lett, 2019(451):79-91.
[30] DACHINENI R, KUMAR D R, CALLEGARI E, et al. Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer[J]. Int J Oncol, 2017, 51(6):1661-1673.
[31] SILLARS-HARDEBOL A H, CARVALHO B, TIJSSEN M, et al. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression[J]. Gut, 2012, 61(11):1568-1575.
[32]TAKAHASHI Y, SHERIDAN P, NIIDA A, et al. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC[J].Ann Oncol, 2015, 26(5):935-942.
[33] AN B C, HONG S, PARK H J, et al. Anti-colorectal cancer effects of probiotic-derived p8 protein[J]. Genes (Basel), 2019, 10(8):624.
[34] ANJOMSHOA A A, LIN Y H, BLACK M A, et al. Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer[J]. Br J Cancer, 2008, 99(6):966-973.
[35] LI Y, LI L, CHEN M, et al. MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation[J]. Mol Oncol, 2018, 12(3):391-405.
[36] ZHONG R, CHEN X, CHEN X, et al. MAD1L1 Arg558His and MAD2L1 Leu84Met interaction with smoking increase the risk of colorectal cancer[J]. Scientific Reports, 2015 (5):12202.
[37] CHEN X, SUN Y Z, ZHANG D H, et al. NRDTD: a database for clinically or experimentally supported non-coding RNAs and drug targets associations[J]. Database (Oxford), 2017(2017):bax057.